Necrocide 1
Based on 2 publication(s) in Google Scholar
Necrocide 1, a necrosis by sodium overload (NECSO) inducer, is a selective transient receptor potential melastatin 4 (TRPM4) agonist with an EC50 of 306.3 nM for human TRPM4. Necrocide 1 triggers TRPM4-dependent necrotic cell death through the induction of sodium influx. Necrocide 1 induces hallmarks of immunogenic cell death incurring calreticulin (CALR) exposure, ATP secretion and high mobility group box 1 (HMGB1) release. Necrocide 1 can be used for the study of breast and prostate cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.55%
- CAS No.: 1247028-61-0
- Formule: C23H27NO3
- Masse moléculaire:365.47
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Necrocide 1
More
Activité biologique
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF7 | IC50 |
0.48 nM
Compound: (S)-38
|
Cytotoxicity against human MCF7 cells after 72 hrs by WST-1 assay
Cytotoxicity against human MCF7 cells after 72 hrs by WST-1 assay
|
[PMID: 20845961] |
| PC-3 | IC50 |
2 nM
Compound: (S)-38
|
Cytotoxicity against human PC3 cells after 72 hrs by WST-1 assay
Cytotoxicity against human PC3 cells after 72 hrs by WST-1 assay
|
[PMID: 20845961] |
In Vitro
Necrocide 1 (compound (S)-38) (72 h)shows antiproliferative activity with an IC50 value of 0.48 and 2 nM for MCF-7 and PC3, respectively[1].
Necrocide 1 (100 μM, 4-24 h) can induce phosphorylation of eIF2α in MCF-7 and A2780 cells[1].
Necrocide 1 (0.1-1000 nM, 24 h) induces necrotic cell death in various human cancer cell lines (MCF7, MB468) with species specificity, showing no effect on mouse cells due to TRPM4 differences[2].
Necrocide 1 (50-100 nM, 1-6 h) triggers massive Na+ influx, K+ efflux, membrane depolarization, and cell edema in MCF7 cells, which is blocked by TRPM4 knockout or sodium depletion[2].
Necrocide 1 (200-1000 nM, 16 h) shows increased cytotoxicity in Cos7 cells expressing gain-of-function TRPM4 mutants linked to cardiac arrhythmias, compared to wild-type TRPM4[2].
Necrocide 1 (1 μM, 0.5-1 h) specifically activates human TRPM4 (EC50 ≈ 306.3 nM) but not mouse TRPM4, as shown by patch-clamp and CETSA assays[2].
Necrocide 1 (100 nM, 3 h)-induced necrosis is inhibited by Clotrimazole (HY-10882) and dihydropyridines in MCF7 cells, blocking Na+ influx[2].
Necrocide 1 (50 nM, 4 h) induces reactive oxygen species (ROS) production in MCF-7 cells[3].
Necrocide 1 (25-100 nM, 12-48 h)-induced cell death is not inhibited by necroptosis inhibitors, ferroptosis inhibitors, pyroptosis inhibitor, or PARP inhibitor in MCF-7 and MDA-MB-468 cells[3].
Necrocide 1 (0.05-1 μM, 48 h) induces calreticulin (CALR) exposure, ATP secretion, and HMGB1 release, which are inhibited by CsA and NecroX-5 (HY-104015) in MCF-7 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF-7 and A2780 cells
-
Concentration:100 μM
-
Incubation Time:4, 24 h
-
Result:Induced the phosphorylation of eIF2α.
Parmacokinetics
| Species | Dose | Route | T1/2 | AUC |
|---|---|---|---|---|
| Rat[1] | 10 mg/kg | i.v. | 1.5 h | 5760 ng·h/mL |
In Vivo
Necrocide 1 (40 mg/kg, i.v., on day 0, with a second injection on day 28) induces significant and sustained tumor regression in PC-3 xenografts in nude mice (effect lasting up to 20 days)[3].
Necrocide 1 (100 mg/kg, i.g., 3 times/week, 2 weeks) reduces tumor growth in PC-3 xenografts in athymic mice[3].
Necrocide 1 (30 mg/kg, i.v., 3 times/week, 2 weeks) suppresses tumor growth in MCF-7 xenografts in athymic mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:PC3 cells (1×107 in 200 µL PBS with 100 µL Matrigel) were subcutaneously implanted into the flanks of female nude rats (NIHRNU-M)[1]
-
Dosage:20 mg/kg
-
Administration:i.v. on days 0 and 7
-
Result:Achieved complete tumor regression in PC3 rat xenograft model at a dose of 20 mg/kg.
Showed no tumor regrowth observed by day 26.
Exhibited no effect on body weights of rats.
Caused no signs of toxicity in rats.
-
Animal Model:PC-3 cells (1×107 in 200 µL PBS mixed with 100 µL Matrigel) were subcutaneously inoculated into female NMRI nude mice (4-5 weeks old)[3]
-
Dosage:40 mg/kg
-
Administration:i.v. on day 0, with a second injection on day 28
-
Result:Induced significant tumor regression in PC-3 xenografts in nude mice at a dose of 40 mg/kg (i.v., on day 0).
Showed sustained tumor regression lasting up to 20 days before regrowth was observed.
Exhibited sensitivity of relapsed tumors to the second injection on day 28, inducing sustained regression again.
Caused no reduction in body weights of mice.
Showed no gross pathological signs in mice.
-
Animal Model:PC-3 cells (1×107 in 200 µL PBS mixed with 100 µL Matrigel) were subcutaneously inoculated into female NMRI nude mice (4-5 weeks old)[3]
-
Dosage:100 mg/kg
-
Administration:i.g., 3 times/week for 2 weeks
-
Result:Consistently reduced PC-3 xenograft tumor growth.
Showed good tolerance in mice.
Caused no body weight reduction in mice.
Induced no gross pathological signs in mice.
-
Animal Model:MCF-7 cells (1×107 in 200 µL PBS mixed with 100 µL Matrigel) were subcutaneously implanted into the flanks of female NMRI nude mice (4-5 weeks old)[3]
-
Dosage:30 mg/kg
-
Administration:i.v. 3 times/week for 2 weeks
-
Result:Successfully suppressed MCF-7 xenograft tumor growth.
Showed good tolerance in mice.
Caused no body weight reduction in mice.
Induced no gross pathological signs in mice.
Chemical Information
-
CAS No. 1247028-61-0
-
Appearance Solid
-
Masse moléculaire 365.47
-
Formule C23H27NO3
-
Color White to off-white
-
SMILES
O=C1NC2=C(C=CC(OC)=C2C)[C@]1(C3CCCCCC3)C4=CC=C(O)C=C4
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
J Chem Inf Model
2026 Mar 16. PMID: 41839059 -
Solvant et solubilité
In Vitro:
DMSO : 100 mg/mL (273.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (6.84 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (6.84 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Pureté et documentation
-
Fiche technique (290 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Christensen MK, et, al. Synthesis and antitumor effect in vitro and in vivo of substituted 1,3-dihydroindole-2-ones. J Med Chem. 2010 Oct 14;53(19):7140-5. [Content Brief]
[2]. Christensen MK, et al. Synthesis and antitumor effect in vitro and in vivo of substituted 1,3-dihydroindole-2-ones. J Med Chem. 2010 Oct 14;53(19):7140-5. [Content Brief]
[3]. Fu W, et al. Persistent activation of TRPM4 triggers necrotic cell death characterized by sodium overload. Nat Chem Biol. 2025 Aug;21(8):1238-1249. [Content Brief]
[4]. Zhang J, et al. Necrocide 1 mediates necrotic cell death and immunogenic response in human cancer cells. Cell Death Dis. 2023 Apr 5;14(4):238. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7362 mL | 13.6810 mL | 27.3620 mL | 68.4051 mL |
| 5 mM | 0.5472 mL | 2.7362 mL | 5.4724 mL | 13.6810 mL | |
| 10 mM | 0.2736 mL | 1.3681 mL | 2.7362 mL | 6.8405 mL | |
| 15 mM | 0.1824 mL | 0.9121 mL | 1.8241 mL | 4.5603 mL | |
| 20 mM | 0.1368 mL | 0.6841 mL | 1.3681 mL | 3.4203 mL | |
| 25 mM | 0.1094 mL | 0.5472 mL | 1.0945 mL | 2.7362 mL | |
| 30 mM | 0.0912 mL | 0.4560 mL | 0.9121 mL | 2.2802 mL | |
| 40 mM | 0.0684 mL | 0.3420 mL | 0.6841 mL | 1.7101 mL | |
| 50 mM | 0.0547 mL | 0.2736 mL | 0.5472 mL | 1.3681 mL | |
| 60 mM | 0.0456 mL | 0.2280 mL | 0.4560 mL | 1.1401 mL | |
| 80 mM | 0.0342 mL | 0.1710 mL | 0.3420 mL | 0.8551 mL | |
| 100 mM | 0.0274 mL | 0.1368 mL | 0.2736 mL | 0.6841 mL |
Necrocide 1 Related Classifications
HY-14307 Related Classifications
Powered by Bioz